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Background: Colorectal cancer (CRC) is one of the most common cancers worldwide. The majority (approximately
60%) of patients with CRC will eventually develop liver metastases, which remain the most common cause of
mortality in these patients. This study aimed to evaluate the therapeutic effect and tolerability of gelatin sponge
particle (GSP)-mediated chemoembolization in the treatment of colorectal liver metastases after systemic
chemotherapy failure.
Methods: This was a single-center retrospective study of 15 patients with colorectal liver metastases, who
underwent GSP-mediated chemoembolization with 50 mg of lobaplatin during the period December 2009 to
December 2010 in the Department of Interventional Radiology, Affiliated Zhongshan Hospital of Dalian University.
Clinical data were retrieved, and the therapeutic effect and tolerability of the treatment were evaluated.
Results: All 15 patients with colorectal liver metastases completed the GSP-mediated chemoembolization. The
therapeutic effect and tolerability were evaluated 3 months after the initial procedure. The tumor lesions in all
patients showed various levels of necrosis and shrinkage. According to the Response Evaluation Criteria in Solid
Tumors (RECIST), one patient achieved complete response (CR), eleven patients achieved partial response (PR), and
three patients achieved stable disease (SD). The overall response rate (CR + PR) was 80%.
Conclusions: GSP-mediated chemoembolization is well tolerated and has a good short-term response rate (80%) in
the treatment of colorectal liver metastases after systemic chemotherapy failure. Collectively, further study of the
long-term effect of GSP-mediated chemoembolization in colorectal liver metastasis in a large cohort is warranted.
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The incidence rate of colorectal cancer ranks second for
malignancies worldwide, and colorectal cancer (CRC) is
the third leading cause of cancer death in developing
countries [1]. Liver metastasis is a common clinical
symptom of CRC, and is one of the main factors that
threatens patients’ lives and affects their survival [2,3]. It
was reported that liver metastases occurred in 60 to 70%
of patients with CRC, 20 to 50% of whom already had
liver metastases when the clinical diagnosis was con-
firmed [4,5]. For patients with liver metastases, surgical
resection is still the primary therapeutic method for* Correspondence: zhangyuewei1001@163.com
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reproduction in any medium, provided the orprolonging survival [6-9]. Unfortunately, only 15 to
30% of patients undergo surgery due to surgical contra-
indications and unwillingness of patients [10]. For pa-
tients with unresectable disease, it is essential to identify
therapies that can provide a high response rate and pro-
long survival.
Transcatheter arterial chemoembolization (TACE) is
an intra-arterial therapy that restricts the arterial vascu-
lar supply of liver metastases. Chemotherapeutic agents
combined with embolization particles result in high
doses of drugs directly to the liver, and selectively cause
ischemic damage to the hepatic tumors. Recently, TACE
has become increasingly important in comprehensive
cancer treatment for colorectal liver metastases [11].
Gelatin sponge particles (GSPs) provide an effectivehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Li et al. World Journal of Surgical Oncology 2013, 11:222 Page 2 of 6
http://www.wjso.com/content/11/1/222absorbable embolization agent. Compared with the con-
ventional permanent embolization agent Lipiodol/
Ethiodol (ethiodized oil), GSP has advantages such as
absorbability, no mass effect, and complete embolism
[12]. Additionally, the GSPs (350 to 560 μm in size) used
in this study have an absorption time of 7 to 14 days
and are more homogeneous than other absorbable
embolization agents such as soluble starch microspheres.
Because of these advantages, GSPs cause less damage to
hepatic function, and complete embolization of the
tumor-feeding arteries can be accomplished.
Although application of GSPs in the treatment of primary
hepatocelluar carcinoma has been reported [13], there are
very few clinical reports of GSPs being used in colorectal
liver metastases. In this study, a retrospective analysis was
conducted on 15 patients with colorectal liver metastases
who underwent GSP-mediated chemoembolization. The
therapeutic effect and tolerability were evaluated.
Methods
Study methods and eligibility criteria
This study was a single-center retrospective review of 15
patients with colorectal liver metastases who underwent
GSP-mediated chemoembolization during the period
December 2009 to December 2010 in our department.
The aim of this study was to evaluate the therapeutic
effect and tolerability of this treatment. All patients under-
went radical surgical resection of the primary CRC. The
intervals between the operation on the primary CRC and
initiation of TACE ranged from 3 months to 2 years. At
the time of considering GSP-mediated chemoembolization
as a ‘salvage’ therapy, all patients had progressive stage
IV disease after failure of systemic chemotherapy (5-
fluorouracil (5-FU)/leucovorin/oxaliplatin (FOLFOX) and
5-FU/leucovorin/irinotecan (FOLFIRI)). Owing to patient
choice (3 cases) and surgical contraindications, such as
bilobar tumor distribution and involvement of major hep-
atic vascular structures (12 cases), these patients were
deemed unresectable. All patients signed informed con-
sent for the treatment. In accordance with institutional
(Affiliated Zhongshan Hospital of Dalian University) eth-
ical practice, alterative treatment options were provided
with explanation of risks and benefits.
Materials used
The GSPs (registration number, CFDA [2006] number
3770360; product standard, YZB/State 2518-77-2004
(Gelatin sponge microparticle embolization agents);
Yilikang Pharmaceutical Co., Ltd. (Hangzhou, China)
used ranged in size from 350 to 560 μm. The chemo-
therapy drug used was lobaplatin for injection (registra-
tion number, CFDA [2006] number H20080359; 50 mg
each; Chang’an International Pharmaceutical Co., Ltd.
(Hainan, China).Interventional treatment
Digital subtraction angiography (DSA), a procedure to
identify tumor vasculature using radiation, was com-
pleted in the 15 patients before chemoembolization. The
interventional treatment was performed using the
Seldinger technique. A licensed surgeon from our de-
partment with 15 years of experience performed these
procedures. Briefly, patients underwent percutaneous
femoral artery catheterization and selective arteriog-
raphy. After determining the source of the tumor-
feeding arteries, the lesion numbers, and the staining in-
tensity, the chemoembolization with 50 mg of lobaplatin
and GSPs was performed on the arteries in the region of
the tumor blood supply to attain complete arterial block-
age. One month after the procedure, enhanced com-
puted tomography (CT) of the upper abdomen was
performed. A second chemoembolization was performed
if the tumor blood supply was not completely blocked.
Chemoembolization was performed once in eight cases
and twice in seven cases.
Criteria for evaluation of therapeutic effect
Routine blood tests for liver and kidney function were
re-examined at days 3 to 7s after the procedure. Re-
examination of hepatic CT was performed at 3 days, 1
month, 3 months, and 6 months after the procedure.
The treatment responses were divided into four categor-
ies according to the Response Evaluation Criteria in
Solid Tumors (RECIST): complete response (CR), partial
response (PR), stable disease (SD), and progressive dis-
ease (PD), defined as follows. CR: all target lesions dis-
appear and the diameters of all the pathological lymph
nodes (including targeted nodes (with a short diameter ≥
15 mm by CT measurement) and non-targeted nodes)
are reduced to less than 10 mm; PR: the sum of all di-
ameters of all target lesions is reduced by 30% from the
baseline level; and SD: the degree of reduction does not
reach the level of PR and the degree of increase does not
reach the level of PD. For PD, there must be at least a
20% increase in the sum of the shortest diameters of all
the measured targeted lesions during the whole experi-
mental study (if the value of baseline measurement is
the smallest, the baseline value is used as reference). The
increase of absolute value of the sum of the diameters
should be >5 mm. Furthermore, the appearance of one
or more new lesions is also considered as PD. The total
response rate equals CR plus PR.
Results
Patient characteristics
In total, 15 patients who received GSP-mediated
chemoembolization in our department during the period
December 2009 to December 2010 were included in this
study. The characteristics of the patients are listed in
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and seven women with a median age of 67 years (range
50 to 80 years). The hepatic function as indicated by
Child-Pugh grade was grade A in eleven patients and
grade B in four. Diagnoses were determined by needle
biopsies, confirming five cases of poorly differentiated
adenocarcinoma, nine cases of intermediately differenti-
ated adenocarcinoma, and one case of well-differentiated
adenocarcinoma. Based on the CT findings, there were
five cases with abdominal lymph node metastases, two
with lung metastases, and one with ascites.
Digital subtraction angiography
Using DSA, three types of tumor vessel characteristics
were seen in these 15 patients: 1) The colorectal liver me-
tastases with adequate blood supply showed a similar ap-
pearance to primary hepatocellular carcinoma, such as
thickened and tortuous hepatic arteries and strong staining
of tumor parenchyma; 2) the colorectal liver metastases
with reduced blood supply showed ring enhancement in
tumors; and 3) the colorectal liver metastases with little
blood supply showed rare, thin, stiff or wrapping tumor
vessels and edge enhancement of tumor parenchyma.
Based on DSA examination, there were eight cases with
adequate blood supply (type 1), three cases with reduced
blood supply (type 2), and four cases with little blood sup-
ply (type 3). DSA examination also showed a single lesion
in five cases and multiple lesions in the other ten (Table 1).Table 1 Characteristics of the enrolled patients
Characteristics




Hepatic function (Child-Pugh grade), n (%)
Grade A 11 (73%)
Grade B 4 (27%)
Histology
Poorly differentiated adenocarcinoma 5 (33%)
Intermediately differentiated adenocarcinoma 9 (60%)
Well-differentiated adenocarcinoma 1 (7%)




Metastasis to other organs, n (%)
No extra-hepatic metastasis 8 (53%)
Lung 2 (13%)
Abdominal lymph node 5 (33%)Therapeutic effects
At 3 days, 1 month, and 3 months after the procedure,
re-examination of hepatic CT showed that all the tumor
lesions exhibited different levels of necrosis and shrink-
age (Figure 1A-D). Hepatic function recovered to pre-
procedure levels by 7 days after the procedure. At 3
months after the initial procedure, we evaluated the
treatment efficacy according to RECIST: patient had CR,
eleven patients had PR and three patients had SD. The
overall response rate (CR + PR) was 80% (Table 2). At 6
months after the procedure without any other therapy,
additional hepatic CT showed that twelve patients had
PR, one patient had SD, and two patients had PD. No
deaths occurred.
Side effects
Treatment-related side effects in the 15 patients enrolled
in the study included fever, mild stomach discomfort,
nausea, and vomiting. Conservative treatment for these
symptoms resolved side effects within 7 days. No serious
complications such as liver and kidney failure, liver ab-
scess, or biloma were seen.
Discussion
Owing to the biological characteristics of the tumors
and the anatomic characteristics of the colorectum,
patients with CRC have a tendency to develop liver me-
tastases [14], and liver metastasis accounts for 60 to
71% of CRC deaths [15]. Surgical resection is still the
primary therapeutic method for prolonging the survival
of patients with colorectal liver metastases, but unfortu-
nately, 70 to 85% of patients are deemed unresectable
when evaluated [16]. For patients with unresectable
liver-dominant disease, TACE is an efficient therapeutic
method [10,11,17,18]. Hepatic arteries supply 95% of the
blood flow to liver neoplasms, whereas 25% of the blood
flow of the normal liver is supplied by hepatic arteries
and 75% is supplied by the portal vein [19,20]. This ana-
tomical feature allows a high concentration of chemo-
therapeutics to directly act on tumor cells through
hepatic arteries, and appropriate embolization agents
can be chosen to block blood supply of tumors. This
therapy has been shown to improve control of hepatic
metastases and further improve quality of life and sur-
vival [21,22].
Arterial embolization agents are currently divided into
two categories: permanent and absorbable. Lipiodol is a
commonly used permanent embolization agent. It has a
superior therapeutic effect for solid tumors with ad-
equate blood supply, but has an inferior therapeutic ef-
fect for those with poor blood supply. Furthermore, it
results in severe liver and kidney damage due to its mass
effect [23], and cannot perform complete embolization
for large-volume liver tumors [24,25]. Recently, the use
Figure 1 Alteration of tumor lesions before and after chemoembolization by hepatic CT. All images are from the same patient. (A) Tumors
showed ring enhancement before embolization; (B) 3 days after embolization, re-examination by CT showed honeycomb-like necrosis of tumor
tissue; (C) tumors displayed shrinkage 1 month after embolization, without intensification in the lesions; (D) 3 months after embolization, more
profound tumor shrinkage was visible.
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increased attention. Several clinical reports have shown
that drug-loaded microspheres can achieve superior ef-
fects in embolization of liver metastases [26-28]. Nitta et
al. reported that single embolization therapy performedTable 2 Therapeutic effects 3 months after the procedure
Patient number Age, years Gender Pathological types Liv
1 80 Male Intermediately differentiated
2 72 Female Poorly differentiated
3 67 Female Intermediately differentiated
4 58 Male Intermediately differentiated
5 60 Female Intermediately differentiated
6 56 Male Intermediately differentiated
7 73 Female Poorly differentiated
8 54 Male Poorly differentiated
9 50 Female Poorly differentiated
10 78 Male Intermediately differentiated
11 68 Male Intermediately differentiated
12 64 Male Well differentiated
13 69 Female Intermediately differentiated
14 68 Male Intermediately differentiated
15 65 Female Poorly differentiated
CR, complete response; PR, partial response, SD: stable disease.through the hepatic arteries in tumor regions in nine
cases with liver metastases, using cisplatin-releasing gel-
atin microspheres of 50 to 100 μm in size, resulted in
two cases of CR, one case of PR, and six cases of SD
[29]. Notably, all the embolization agents used aboveer lesions, b Metastasis to other organs
before chemoembolization
Embolizations, n Effect
2 No 1 PR
1 No 2 PR
1 Lung 2 SD
> 5 No 1 PR
2 No 2 CR
1 No 1 PR
> 5 Abdominal lymph node 2 PR
> 5 Lung 2 PR
> 5 Abdominal lymph node 1 SD
> 5 Abdominal lymph node 2 PR
> 5 No 1 PR
1 No 1 PR
1 Abdominal lymph node 2 PR
> 5 Abdominal lymph node 1 PR
> 5 No 1 SD
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complete embolization for large-volume liver tumors
cannot be achieved, and a risk of liver failure, gallbladder
necrosis, liver abscesses, and other serious complications
exists [12,30].
GSPs are effective absorbable embolization agents that
have been used in clinical practice [12]. The GSP we used
in this study have an absorption time of 7 to 14 days and
increased homogeneity, and therefore cause less damage
to hepatic function and can be used to perform complete
embolization of the tumor-feeding arteries. In our study,
CT scans showed honeycomb-like necrosis throughout
the tumor area 3 days after the procedure, and the hepatic
function recovered to pre-procedure levels by 7 days. At 1
month after the procedure, the tumors showed various
levels of low-density necrosis and shrinkage, and were ef-
fectively controlled.
Conclusion
Application of GSPs as an embolization agent combined with
50 mg of Lobaplatin can completely block the arteries of
metastatic liver lesions and achieve a high tumor response
rate (80%). Other advantages include no mass effect, reduced
liver damage, and rapid recovery of post-procedure hepatic
function. GSP-mediated chemoembolization achieved
good short-term effects in the treatment of colorectal
liver metastases. However, the long-term effects remain
to be elucidated and studies with larger sample size are
warranted.
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